FDA approves ‘female Viagra,’ could tap potential $1 billion market

The U.S. drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals’ drug to restore sexual desire in premenopausal women, the la

China grounds domestic fleet of Boeing 737 Max 8 jets after Ethiopian Airlines crash: CAAC
Southwest pilots sue Boeing, alleging more than $100M in lost wages after 737 MAX grounding
Amazon workers in United States, Germany go on strike on Prime Day

The U.S. drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals’ drug to restore sexual desire in premenopausal women, the latest attempt to come up with a therapy that some have dubbed as “female Viagra.”READ MORE: Why some people have sex even when they aren’t in the moodThe therapy, Vyleesi, will compete in a market which has seen previous attempts fail. Analysts have said that a drug that safely and effectively treats loss of sexual desire in women could eventually reach annual sales of about $1 billion.Palatin’s shares jumped 44 per cent to $1.93, while Amag shares rose 11.5 per cent after market.Vyleesi, chemically known as bremelanotide, activates pathways in the brain involved in sexual desire, helping premenopausal women with hypoactive sexual desire disorder (HSDD).WATCH: 20 years since the little blue pill got the green light

COMMENTS

WORDPRESS: 0
DISQUS: 0